Core Viewpoint - Coty Inc. is under investigation for potential violations of federal securities laws, following a significant decline in stock price due to disappointing financial results and misrepresentation of product demand [2][4][5]. Group 1: Company Overview - Coty Inc. is one of the largest beauty companies globally, with a diverse portfolio that includes fragrance, color cosmetics, and skin and body care products. Prestige fragrances contribute to 60% of the company's revenues [4]. Group 2: Financial Performance - On August 20, 2025, Coty reported disappointing financial results for Q4 and FY 2025, citing issues such as weaknesses in U.S. execution, retailer inventory buildup, and a slowdown in cosmetics sales. The stock price fell from $4.86 to $3.81, a decline of over 21% [5]. Group 3: Investigation Details - The investigation by Bleichmar Fonti & Auld LLP is focused on potential securities fraud related to Coty's claims about strong demand for its Prestige fragrances, which contradicted the reality of overstocked inventory due to declining product demand [2][4].

Core Viewpoint - The James Hardie Industries plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors about the strength of its North America Fiber Cement segment during a period of inventory destocking [1][4]. Company Overview - James Hardie Industries plc designs and manufactures a variety of fiber cement building products, operating manufacturing plants in both the United States and Australia [3]. Allegations of the Lawsuit - The lawsuit claims that despite early signs of inventory destocking by customers in April and May 2025, James Hardie executives made false assurances to investors about the segment's strength and denied any inventory destocking was occurring [4]. - It is alleged that the company engaged in practices resembling fraudulent channel stuffing, misleading investors about sustainable customer demand [4]. - On August 19, 2025, James Hardie reported a 12% decline in sales for the North America Fiber Cement segment due to the previously undisclosed customer destocking, leading to a stock price drop of over 34% [5]. Legal Process - Investors who purchased James Hardie common stock during the specified class period (May 20, 2025, to August 18, 2025) have until December 23, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][6]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7]. - The firm has a strong track record, being ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3][5]. - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which posed health risks to users [5]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom's design changes rendered the G6 and G7 systems less reliable, overstating the devices' enhancements and functionality [5]. - It is claimed that DexCom downplayed the severity of issues related to the G7 devices, which increased the risk of regulatory scrutiny and potential legal repercussions [5]. - The public statements made by DexCom during the Class Period are described as materially false and misleading, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a securities class action lawsuit due to regulatory setbacks and significant stock declines, with allegations of misleading statements regarding its business operations and therapeutic candidates [1][2][3]. Allegations - The lawsuit claims that Telix overstated the developmental progress and commercial prospects of its prostate cancer therapeutic candidates, specifically TLX591 and TLX592 [3]. - It is alleged that the company misrepresented the stability, quality, and regulatory compliance of its third-party supply chain and manufacturing partners, which were critical to its regulatory applications [4]. Regulatory Events Impacting Stock - The first significant stock decline occurred after Telix disclosed receiving a subpoena from the SEC on July 22, 2025, leading to a more than 13% drop in the price of Telix's American Depositary Shares (ADSs) over two trading sessions [5]. - A more severe decline followed the announcement of a Complete Response Letter (CRL) from the FDA on August 28, 2025, regarding TLX250-CDx (Zircaix), which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package, resulting in a further decline of over 21% in the stock price [6][7]. Investigation - Hagens Berman is actively investigating the claims against Telix, focusing on the discrepancies between the company's long-term assurances and the regulatory revelations that followed [8].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. alleging that the company made misleading statements regarding the reliability and safety of its G6 and G7 glucose monitoring devices, which were modified without FDA approval, leading to health risks for users [2][4]. Summary by Sections Lawsuit Details - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7 devices, which compromised their reliability and presented health risks to users [2]. - Allegations include overstating the enhancements and reliability of the G7, downplaying the severity of issues with the devices, and exposing the company to increased regulatory scrutiny and potential legal consequences [2]. Regulatory Concerns - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management issues, resulting in a share price drop of $7.12, or approximately 9.15%, from $77.84 to $70.72 [3]. - The FDA's published warning letter on March 25, 2025, confirmed that DexCom had adulterated its devices, leading to a further decline in share price by $1.77, or about 2.4%, from $75.32 to $73.55 [4]. Market Reactions - On September 8, 2025, Oppenheimer downgraded DexCom's rating to "perform" from "outperform," citing concerns over the G7's accuracy and performance, which caused a decline in share price by $2.51, or approximately 3.1%, from $80.51 to $78.00 [5]. - A report by Hunterbrook Media LLC on September 18, 2025, highlighted severe health risks associated with the G7 devices, linking them to hospitalizations and fatalities, resulting in a significant share price drop of $8.33, or about 11%, from $75.78 to $67.45 [7].

Core Viewpoint - A class action lawsuit has been filed against StubHub Holdings, Inc. for alleged securities fraud and unlawful business practices following disappointing financial results reported after its IPO [2]. Group 1: Class Action Lawsuit - The lawsuit concerns whether StubHub and its officers engaged in securities fraud or other unlawful business practices [2]. - Investors have until January 23, 2026, to request to be appointed as Lead Plaintiff if they purchased StubHub securities during the Class Period [2]. Group 2: Financial Performance - StubHub conducted its IPO on September 17, 2025, offering 34,042,553 shares at $23.50 each [2]. - The company reported a negative free cash flow of $4.6 million for Q3 2025, a 143% decrease from the positive $10.6 million reported in the same quarter the previous year [2]. - Net cash provided by operating activities was $3.8 million, down 69.3% from $12.4 million in the prior year [2]. - The decline in free cash flow was attributed to changes in the timing of payments to vendors [2]. Group 3: Stock Market Reaction - Following the financial results announcement, StubHub's stock price dropped by $3.95, or 20.9%, closing at $14.87 per share on November 14, 2025 [2].

Core Viewpoint - Freeport-McMoRan Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to safety issues at its Grasberg mine in Indonesia, which resulted in worker fatalities and significant stock price declines [1][3][5]. Group 1: Lawsuit Details - The class action lawsuit is titled Reed v. Freeport-McMoRan Inc. and covers purchasers of Freeport-McMoRan securities from February 15, 2022, to September 24, 2025 [1]. - The lawsuit alleges that Freeport-McMoRan failed to ensure adequate safety measures at the Grasberg Block Cave mine, leading to heightened risks for workers [3]. - On September 9, 2025, Freeport-McMoRan reported a significant incident at the Grasberg mine, which restricted evacuation routes for workers and led to a nearly 6% drop in stock price [4]. Group 2: Incident Impact - Following the September 9 incident, Freeport-McMoRan disclosed that two team members were fatally injured and that production could be approximately 35% lower than pre-incident estimates for 2026, resulting in a nearly 17% decline in stock price [5]. - An article published on September 25, 2025, highlighted the potential strain on Freeport-McMoRan's relationship with the Indonesian government due to the production halt, causing an additional stock price drop of over 6% [6]. Group 3: Legal Process - Investors who purchased Freeport-McMoRan securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of all class members [7]. - The lead plaintiff has the authority to select a law firm for litigation, and participation as lead plaintiff does not affect the ability to share in any potential recovery [7]. Group 4: Company Background - Freeport-McMoRan is engaged in mining operations in North America, South America, and Indonesia, with significant activities at the Grasberg Copper and Gold Mine in Papua [2].

Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. alleging securities fraud that affected investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [2]. - It is alleged that the quality of Telix's supply chain and partners was also materially overstated [2]. - As a result, statements made by defendants regarding Telix's business, operations, and prospects were materially false and misleading [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's acquisition of the infant formula business from Nestlé was significantly underinvested in maintenance and operational improvements [2]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2]. - The complaint points out significant manufacturing deficiencies in the facility related to the infant formula business [2]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [2]. - The positive statements made by the defendants regarding the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to misleading statements about the efficacy of its drug Efzofitimod, which led to significant stock price decline [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for aTyr investors affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [1]. - Defendants allegedly made positive statements about Efzofitimod while concealing adverse facts regarding its efficacy, particularly its ability to allow patients to taper steroid usage [2]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in an 83.2% decline in stock price from $6.03 to $1.02 per share in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].